

China Pharmaceuticals Industry Report - H2, 2013

<https://marketpublishers.com/r/C4253B90F87EN.html>

Date: January 2014

Pages: 34

Price: US\$ 475.00 (Single User License)

ID: C4253B90F87EN

Abstracts

This report reviews the current trends and market outlook in China's pharmaceuticals and health care industry. It also discusses the stock performance and financial highlights for leading players in the sector, including Shanghai Pharma, China National Accord (Sinopharm Accord), Harbin Pharma, Yunnan Baiyao, and Huadong Medicine.

Chinese government spending on health care grew at a compounded annual growth rate (CAGR) of 32.01% between 2005 and 2012. As a result of rising disposable income and health awareness, health care spending per capita in both urban and rural areas is trending up. Nevertheless, public health care expenditure as percentage of total GDP in China still trails many developed economies like the United States, Canada, and Germany.

Revenues from the Chinese pharmaceutical industry grew by a CAGR of 23.3% from 2006 to 2012. The Chinese government has allocated RMB 1.49bn to a subsidy fund to support the development of traditional Chinese medicine in 2013. Chemical drugs preparation, Chinese-prepared medicine, and chemical medicine were the three largest product categories in the pharmaceutical industry in the first half in 2013. Total sales of Chinese-prepared medicines topped more than 90% of total industry revenue in 2012.

Key Points:

Firms surveyed in this report include Shanghai Pharmaceuticals Holding Co. Ltd. (Shanghai Pharma), China National Accord Medicines Corp. Ltd. (Sinopharm Accord), Harbin Pharmaceutical Group Co. Ltd. (Harbin Pharma), Yunnan Baiyao Group Co. Ltd. (Yunnan Baiyao), and Hangzhou Huadong Medicine Co. Ltd. (Huadong Medicine).

Health care spending per capita in urban and rural China increased at a CAGR

of 9.15% and 18.63%, respectively, between 2004 and 2012.

Sales of traditional Chinese medicines grew at a CAGR of 21.54% between 2002 and 2012.

Revenues from the Chinese pharmaceutical industry grew by a CAGR of 23.3% from 2006 to 2012.

Contents

1. INDUSTRY PROFILE

- 1.1 Market size and value
- 1.2 Social security and health insurance
- 1.4 Health care infrastructure
- 1.4 Pharmaceutical industry overview
- 1.5 Regulations and policies

2. MARKET TRENDS AND OUTLOOK

- 2.1 Social health care insurance system
- 2.2 Traditional Chinese medicine
- 2.3 Over-the-Counter (OTC)
- 2.4 Vaccines

3. LEADING PLAYERS AND COMPARATIVE MATRIX

- 3.1 Leading players
 - 3.1.1 Shanghai Pharmaceuticals Holding Co. Ltd.
 - 3.1.2 China National Accord Medicines Corp. Ltd.
 - 3.1.3 Harbin Pharmaceutical Group Co. Ltd.
 - 3.1.4 Yunnan Baiyao Group Co. Ltd.
 - 3.1.5 Hangzhou Huadong Medicine Co. Ltd.
- 3.2 Comparative Matrix
- 3.3 SWOT Analysis

4. TABLES AND CHARTS

- Table 1: Number of Beds by Type of Hospital
- Table 2: New Drug Classifications in China
- Table 3: Top 10 Major Traditional Chinese Medicinal Materials
- Table 4: Major Type II Vaccines
- Table 5: Shanghai Pharma Financial Highlights
- Table 6: Sinopharm Accord Financial Highlights
- Table 7: Harbin Pharma Financial Highlights
- Table 8: Yunnan Baiyao Financial Highlights
- Table 9: Huadong Medicine Financial Highlights

Table 10: Selected Peer Comparison of Key Financial Ratios

Chart 1: Total Government Health Care Expenditure

Chart 2: Total Health Care Expenditure over GDP in 2011

Chart 3: Health Care Expenditure per Capita in Urban and Rural China

Chart 4: Total Government Expenditure on Public Health

Chart 5: Social Security Medical Fund in Urban Areas

Chart 6: Retirees in Urban Areas Insured under Social Security Medical Fund

Chart 7: Health Insurance in China

Chart 8: Number of Hospitals in China

Chart 9: Hospitals by Type

Chart 10: Total Assets of Pharmaceutical Industry in China

Chart 11: Revenue and Net Profit Margin of Pharmaceutical Industry in China

Chart 12: Pharmaceutical Industry Revenue by Product Category 1H2013

Chart 13: Pharmaceutical Market by Therapeutic Area 2011

Chart 14: Accumulated Balance of Social Medical Insurance Programs

Chart 15: Revenue of Traditional Chinese Medicine

Chart 16: Distribution Channel of OTC Pharmaceuticals

Chart 17: Shanghai Pharma Segment Revenue 2012

Chart 18: Sinopharm Accord Segment Revenue 2012

Chart 19: Harbin Pharma Segment Revenue 2012

Chart 20: Yunnan Baiyao Segment Revenue 2012

Chart 21: Huadong Medicine Segment Revenue 2012

I would like to order

Product name: China Pharmaceuticals Industry Report - H2, 2013

Product link: <https://marketpublishers.com/r/C4253B90F87EN.html>

Price: US\$ 475.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C4253B90F87EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970